BackRain Oncology Overview

Rain Oncology Operating Income

Latest operating income for RAIN: $-8.8M.

Get informed when a big investor buys or sells

+ Follow

Quarterly Operating Income

$-1925787.00
43.14% YoY

As of Mar 31, 2026

Annual Operating Income (TTM)

$-8768481.00
57.98% YoY

Trailing 12 months ending Mar 31, 2026

Average Operating Income (Comparison Companies)

Operating Income History

Operating Income Comparison

Annual Operating Income Growth Rate (%)

Annual Operating Income Growth (Absolute)

Rain Oncology (RAIN) FAQ

Rain Oncology posts a operating income of $-8.8M as of March 2026. That compares with $-5.6M in the prior-year period — down 58.0% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Rain Oncology's operating income was $-5.6M. The latest reading is $-8.8M — a 58.0% year-over-year decrease (period ending March 2026). Use the history and growth charts on this page for a longer lookback.

Operating Income is one piece of Rain Oncology's financial statement story. At $-8.8M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for RAIN's operating income usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Rain Oncology's other metric pages and overview cover the third.

Judging Rain Oncology against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in operating income easier to interpret. Start with $-8.8M here, then scan peer and history charts to see if the gap is persistent.